Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Other Working Capital Changes (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Working Capital Changes for 11 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes changed N/A to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $5.0 million for FY2025, 776.28% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $4.2 million at Crescent Biopharma, up from $1.3 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $4.2 million in Q4 2025, with the low at -$886131.0 in Q3 2021.
  • Average Other Working Capital Changes over 5 years is $379080.9, with a median of -$17107.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes surged 1616.34% in 2022, then tumbled 197.4% in 2023.
  • Over 5 years, Other Working Capital Changes stood at -$40932.0 in 2021, then soared by 1616.34% to $620669.0 in 2022, then crashed by 197.4% to -$604542.0 in 2023, then soared by 70.63% to -$177575.0 in 2024, then surged by 2445.49% to $4.2 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $4.2 million, $1.3 million, and $6718.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.